Lipid treatment assessment project II in Thailand (LTAP-II Thailand)

Journal of the Medical Association of Thailand

Volumn 91, Issue 6, 2008, Pages 836-845

  Nitiyanant, Wannee ^a   Sritara, Piyamitr ^b   Deerochanawong, Chaicharn ^c   Ngarmukos, Pungchai ^d   Koanantakul, Banharn ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c RAJAVITHI HOSPITAL   (Thailand)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^e BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

Author keywords

Hypercholesterolemia; Treatment

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; HEALTH PROGRAM; HEALTH SERVICE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICIAN; PRESCRIPTION; RANDOMIZATION; RISK ASSESSMENT; RISK FACTOR; SMOKING; THAILAND; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROGRAM EVALUATION; RISK ASSESSMENT; RISK FACTORS; THAILAND;

EID: 47149095427     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000; 321:983-6.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-57.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
5. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-39.
6. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002; 176:211-5.
7. Pyorala K, Lehto S, De Bacquer D, De Sutter J, Sans S, Keil U, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EURO ASPIRE I AND II surveys. Diabetologia 2004; 47:1257-65.
8. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459-67.
9. Division of International Health, Bureau of Health Policy and Planning, Office of the Permanent Secretary and Ministry of Public Health. Thailand health profile, 1997-1998. Bangkok: Express Transportation Organization; 2000.
10. Nitiyanant W, Ngarmukos P, Koanantakul B. Lipid treatment assessment project (L-TAP) in Thailand. Intern Med J Thai 2001; 17:246-52.
11. Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003; 88:3212-7.
12. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.
13. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 2005; 149: e1.
14. McKenney JM, Davidson MH, Saponaro J, Thompson PD, Bays HE. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol 2005; 46:594-9.
15. Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 2002; 22:385-98.
16. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990; 31: 1149-72.
17. Patel A, Woodward M, Stolk R, Suriyawongpaisal P, Neal B. Serum lipid levels and the prevalence of dyslipidaemia among rural and urban Thai adults -are the NCEP III guidelines appropriate? J Med Assoc Thai 2005; 88:1242-50.
18. Hata Y, Nakajima K. Life-style and serum lipids and lipoproteins. J Atheroscler Thromb 2000; 7: 177-97.